Aegon provides first quarter 2020 update
Net income of EUR 1,270 million, reflecting fair value gains
● Underlying earnings before tax were EUR 366 million reflecting adverse mortality and impacts from lower interest rates in the Americas, and limited COVID-19 related non-life claims in the Netherlands
● Net income of EUR 1,270 million reflects fair value gains of EUR 1,372 million, driven by a reduction in the valuation of the liabilities in the Netherlands, reflecting wider credit spreads. This was partly offset by fair value losses in the US from unhedged risks on variable annuities and underperformance of investments. Hedge programs across the group were highly effective for the targeted risks
● Other charges of EUR 162 million mainly related to a provision for a class action settlement, restructuring charges, and IFRS 9 / 17 project costs, partly offset by a gain on sale of Aegon’s stake in joint ventures in Japan
● Return on equity of 7.0% in the first quarter of 2020; very unlikely to reach annual 10% return on equity target, given the extraordinary circumstances due to the COVID-19 pandemic
Gross deposits of EUR 52 billion; net outflows of EUR 1 billion
● Gross deposits were EUR 52 billion; net outflows of EUR 1 billion caused by Variable Annuities and Mutual Funds in the Americas, partly offset by third-party inflows at Asset Management
● New life sales were EUR 206 million; sales in the US were under competitive pressure and impacted by the phasing out of certain whole life products, while sales in China benefitted from the e-commerce sales model
● Accident & health insurance new premium production was EUR 76 million and property & casualty new premium production was EUR 36 million
Solid capital and Holding excess cash position
● Solvency II ratio increased to 208%, as the negative impact of market movements in the US was more than offset by normalized capital generation and the benefit of a higher EIOPA volatility adjustment in the Netherlands
● The capital positions in each of Aegon’s three main units remained above the bottom end of their respective target ranges
● Normalized capital generation after holding expenses was EUR 311 million
● Holding excess cash increased to EUR 1.4 billion, driven by a EUR 100 million remittance from the Netherlands and EUR 153 million proceeds from the sale of Aegon’s stake in joint ventures in Japan
Statement of Matt Rider, CFO
“Given the extraordinary circumstances due to the COVID-19 pandemic, we provide a condensed update of our results today. In the first quarter of 2020, underlying earnings in Europe, Asia and Asset Management held up well. However, earnings in the United States were negatively affected by the drop in interest rates as a result of the COVID-19 crisis, and unfavorable mortality experience, which was largely unrelated to COVID-19. This resulted in underlying earnings before tax of 366 million euros for the Group. Net income of 1.3 billion euros benefited from effective hedge programs and the favorable impact of credit spread movements on the valuation of our liabilities.
We are acutely aware of the disruption that the COVID-19 pandemic has caused for our customers, employees and the communities in which we operate. Our priority is to protect the health, safety and security of our employees, and fulfill our responsibilities towards all our stakeholders. I am pleased to say that our resilience, experience and business continuity plans have enabled us to serve our customers at a high level. Our purpose, to help them achieve a lifetime of financial security, remains the same.
The uncertainty around how the pandemic will play out and the continued economic impact it will have, make it difficult to provide a full assessment of COVID-19 related impacts on our medium-term targets, while it is very unlikely that we will reach our annual 10% return on equity target in 2020.
I am pleased that we have maintained a strong balance sheet and liquidity position at the Group and in our main units in these extraordinary times. We are taking management actions to protect the economic value of the balance sheet and our capital position, and are looking at opportunities to increase our cost efficiency. Our aim is to position the company well as we emerge from the COVID-19 crisis to ensure the best possible outcome for all our stakeholders.”
|EUR millions 9||Notes||1Q 2020|
|Underlying earnings before tax|
|Holding and other|
|Underlying earnings before tax|
|Fair value items|
|Realized gains / (losses) on investments|
|Other income / (charges)|
|Income before tax|
|Net income / (loss)|
|Net income / (loss) attributable to:|
|Owners of Aegon N.V.|
|Net underlying earnings|
|Shareholders' equity excluding revaluation reserves|
|Gross Financial Leverage ratio|
|Return on equity|
|Commissions and expenses|
|of which operating expenses|
|Gross deposits (on and off balance)|
|Total gross deposits|
|Net deposits (on and off balance)|
|Total net deposits excluding run-off businesses|
|Total net deposits / (outflows)|
|New life sales|
|Life single premiums|
|Life recurring premiums annualized|
|Total recurring plus 1/10 single|
|New life sales|
|Total recurring plus 1/10 single|
|New premium production accident and health insurance|
|New premium production property & casualty insurance|
|Market consistent value of new business|
|Total market consistent value of new business|
Underlying earnings before tax
Aegon’s underlying earnings before tax were EUR 366 million in the first quarter of 2020. This reflects adverse mortality experience and impacts from lower interest rates in the Americas. Underlying earnings in the Netherlands, United Kingdom, International and Asset Management included limited unfavorable impacts from the COVID-19 pandemic in the first quarter of this year.
Underlying earnings from the Americas were EUR 142 million. Earnings were impacted by EUR 62 million adverse mortality experience and EUR 37 million unfavorable intangible adjustments as a consequence of lower interest rates. Adverse mortality resulted from an increase in large claims at older ages in universal life and traditional life concentrated in March, with only a small portion driven by COVID-19 related claims. Long-Term Care benefitted from increased claims terminations due to higher mortality. This was partly offset by adverse claims experience in Medicare supplement insurance, which is partly seasonal. Earnings from Retirement Plans were under pressure from lower fees caused by lower average asset balances, and adverse impact from market volatility. Earnings from variable annuities were impacted by higher benefit reserves, as account values became less than guaranteed values on part of the portfolio due to adverse market conditions in March, while net fee income held up well as a result of higher average asset balances. Furthermore, expenses in the US were elevated due to EUR 14 million one-off expenses, contractor related expenses, and technology spend to support strategic initiatives.
Underlying earnings before tax from Aegon’s operations in the Netherlands were EUR 154 million. Life earnings were negatively impacted by a change in the treatment of longevity and mortality results in underlying results, as well as higher reinsurance costs following the longevity reinsurance transaction in December 2019. Furthermore, there were EUR 9 million non-life claims from travel insurance and disability insurance due to the COVID-19 crisis. Banking earnings were supported by growing interest income, reflecting balance sheet growth. Earnings benefitted from lower pension costs as employees began accruing pension benefits in a defined contribution plan instead of the now closed defined benefit plan.
In the United Kingdom, underlying earnings before tax were EUR 44 million. Fee income was strong in the first two months of the quarter and also benefitted from the hedge program to partially protect fee income against declining equity markets. Furthermore, expenses reflect the benefit from cost synergies from the Cofunds integration.
Underlying earnings before tax at International were EUR 44 million and benefitted from portfolio growth in several countries and a favorable claims ratio in Spain. These were largely offset by unfavorable intangible adjustments in the High Net Worth businesses due to lower interest rates.
Underlying earnings before tax from Aegon Asset Management were EUR 38 million, reflecting performance fees in Aegon’s Chinese asset management joint venture Aegon Industrial Fund Management Company (AIFMC), driven by strong performance of the New Horizons multi-asset fund in the beginning of the quarter.
The earnings from the Holding were a loss of EUR 56 million.
Net income was EUR 1,270 million and, next to underlying results before tax, reflects fair value gains of EUR 1,372 million, which were only partly offset by Other charges of EUR 162 million and net impairments of EUR 59 million.
Fair value items
The gain from fair value items amounted to EUR 1,372 million for first quarter of 2020 as fair value losses in the Americas were more than offset by fair value gains in the Netherlands and the United Kingdom.
Fair value gains in the Netherlands were EUR 1,931 million as the Liability Adequacy Test (LAT) deficit reduced significantly in the first quarter of 2020. This was driven by an increase in the illiquidity premium, which decreased the fair value of IFRS insurance liabilities. The increase in the illiquidity premium reflects widening credit spreads as a consequence of the COVID-19 pandemic. The negative impact of lower risk-free interest rates on the LAT was more than offset by fair value gains on hedges and the guarantee provision.
In the United Kingdom, fair value gains of EUR 145 million were driven by gains on hedges to protect both the solvency position and fee income.
Fair value gains in the Netherlands and United Kingdom were partly offset by fair value losses of EUR 660 million in the Americas. This amount reflects losses on unhedged risks, impacting fair value items with an accounting match related to variable annuities and fair value items without an accounting match related to indexed universal life products. The hedge programs were highly effective for the targeted risks. Fair value losses also included the underperformance of alternative assets, and negative fair value changes on credit derivatives written on corporate and sovereign bonds, caused by spread widening.
Realized gains on investments
Realized gains on investments amounted to EUR 14 million, reflecting realized gains in the Americas from normal trading activity.
Net impairments amounted to a loss of EUR 59 million. This was primarily caused by EUR 32 million net impairments in the US related to bankruptcies in the energy sector, and EUR 20 million impairments in the Netherlands related to an associate company of Aegon.
Other charges of EUR 162 million were caused by a EUR 52 million provision for a settlement of class action litigation related to monthly deduction rate adjustments on certain universal life policies in the US; EUR 49 million restructuring expenses, mainly in the US and the UK; EUR 39 million model conversion charges and an interest rate related adjustment in the US; EUR 31 million IFRS 9 / 17 project costs; EUR 27 million policyholder taxes in the UK, which are fully offset in the Income tax line; and a EUR 14 million impairment of intangibles in the UK related to the Cofunds acquisition in 2016 due to expected lower future cash flows reflecting the current market circumstances. This was partly offset by a EUR 53 million gain on the sale of Aegon’s stake in joint ventures in Japan.
The result from run-off businesses was a loss of EUR 3 million.
Income tax amounted to a charge of EUR 258 million, while income before tax was EUR 1,529 million, resulting in an effective tax rate on income before tax of 16.9% in the first quarter of 2020. The effective tax rate reflects a beneficial tax rate impact following a substantial change in the deferred tax position in the Netherlands.
Return on equity
Return on equity was 7.0% in the first quarter of 2020.
Operating expenses were EUR 991 million and included EUR 49 million restructuring expenses and EUR 30 million IFRS 9 / 17 project costs. Elevated expenses in the US included EUR 14 million one-off expenses, increased contractor related expenses and technology spend to support strategic initiatives. These were partly offset by cost synergies in the United Kingdom and the benefit from lower pension costs in the Netherlands, as employees began accruing pension benefits in a defined contribution plan instead of the now closed defined benefit plan.
Gross deposits were EUR 52 billion in the first quarter of 2020, mainly from Asset Management and the Americas. The EUR 32.7 billion gross deposits at Asset Management were driven by AIFMC, which recorded significant inflows in both new and existing funds. Gross deposits in the Americas were EUR 12.4 billion, mainly from Retirement Plans, Mutual Funds and Variable Annuities. In the Netherlands, gross deposits were EUR 3.7 billion, reflecting bank deposits at Knab and pension deposits at Aegon Cappital. Gross deposits of EUR 3.0 billion in the United Kingdom were driven by retail and workplace inflows on the platform.
Residential mortgage sales in the Netherlands were strong at EUR 2.5 billion.
Net outflows amounted to EUR 1.0 billion for the first quarter of 2020, caused by the Americas and the United Kingdom. The net outflows of EUR 1.6 billion in the Americas were caused by outflows in Variable Annuities, reflecting the maturity of the block, and Mutual Funds, due to higher market volatility. The United Kingdom saw limited outflows of EUR 0.2 billion, caused by the Existing Business. Asset Management recorded net third-party inflows of EUR 0.6 billion, driven by AIFMC, following successful new fund launches and inflows in equity products. There were net inflows of EUR 0.1 billion in the Netherlands, reflecting net inflows at Aegon Cappital.
New life sales were EUR 206 million in the first quarter of 2020. In the Americas, sales were EUR 88 million, mainly from indexed universal life (IUL) and traditional life sales. In traditional life sales, term pricing actions late in 2019 have been well received, while sales were negatively impacted by the phasing out of certain whole life products. IUL sales have held up well despite challenging market conditions and increased competition. Sales at International were EUR 79 million, reflecting continued strong sales by Aegon’s insurance joint venture in China as a result of strong sales through the platform of a large e-commerce partner and strong performance from the agency channel with a new whole life product. Sales at the High Net Worth business were under pressure due to the COVID-19 crisis. In the Netherlands, sales were EUR 26 million and reflect strong single premium pension production, partly offset by individual life single premium production as Aegon exited that market in March. Protection products in the United Kingdom continued to perform well with EUR 12 million new sales.
New accident & health premium production was EUR 76 million, reflecting favorable voluntary benefit and long-term care sales in the US, as well as strong disability sales in the Netherlands. New property & casualty production was EUR 36 million, reflecting good sales performance in Spain and Hungary.
Market consistent value of new business
Market consistent value of new business (MCVNB) was EUR 100 million. In the Americas, MCVNB amounted to EUR 35 million, driven by Life Insurance, Accident & Health insurance and Retirement Plans, which was largely offset by negative margins on Variable Annuities, reflecting the significant decline in interest rates. MCVNB in the United Kingdom was EUR 42 million, driven by increased volumes of high margin workplace and group pension products. International recorded MCVNB of EUR 24 million, reflecting lower interest rates, partly compensated by strong sales volumes in China. In the Netherlands, MCVNB was EUR (1) million due to negative margins in disability insurance.
Shareholders’ equity increased by EUR 1.3 billion in the first quarter of 2020 to EUR 23.8 billion on March 31, 2020, driven by EUR 1.3 billion net income, a EUR 0.5 billion gain from the remeasurements of defined benefits plans as a result of credit spread widening, and a EUR 0.1 billion increase in the foreign currency translation reserve. This was partly offset by a EUR 0.6 billion decrease in revaluation reserves due to credit spread widening. Shareholders’ equity excluding revaluation reserves increased by EUR 1.8 billion to EUR 18.5 billion at the end of the first quarter of 2020 or EUR 8.99 per share.
Gross financial leverage ratio
The gross financial leverage ratio improved by 200 basis points to 26.6% in the first quarter of 2020, which is at the lower end of Aegon’s 26% – 30% target range. The improvement was the result of the increase of shareholders’ equity excluding revaluation reserves.
Holding excess cash
Aegon’s holding excess cash position increased from EUR 1,192 million to EUR 1,379 million during the first quarter of this year, which is well within the target range of EUR 1.0 billion to EUR 1.5 billion. The increase was driven by EUR 116 million remittances from subsidiaries, of which EUR 100 million from the Netherlands, and EUR 153 million proceeds from the sale of Aegon’s stake in joint ventures in Japan. This was partly offset by EUR 21 million capital injections in subsidiaries to support the execution of business plans and EUR 63 million holding funding and operating expenses.
Capital generation after holding expenses amounted to EUR 845 million in the first quarter of 2020 This included a positive impact from market movements of EUR 343 million and favorable one-time items of EUR 192 million. As a consequence, normalized capital generation amounted to EUR 311 million. Normalized capital generation in the United States was under pressure from unfavorable mortality experience, while the Netherlands benefitted from high capital generation in the Service Business related to mortgage transactions.
Solvency II ratio
Aegon’s Group Solvency II ratio increased from 201% to 208% during the first quarter of 2020, and remained above the target zone of 150% – 200%. The ratio increased primarily due to normalized capital generation and, on balance, the positive impact from market movements. The significant negative overall impacts from lower equity markets and lower interest rates, primarily in the US, were more than offset by the significant positive impact of the increased EIOPA volatility adjustment on the Solvency II ratio of the Netherlands.
The estimated RBC ratio in the United States decreased to 376% on March 31, 2020, compared with 470% on December 31, 2019, and remained above the bottom-end of the target range of 350%. The severe disruption experienced in the first quarter of 2020, as a result of the COVID-19 pandemic, led to significant negative market impacts. Falling interest rates and equity markets were the primary drivers. Furthermore, widening credit spreads had a negative impact on unhedged credit risk, and there were limited adverse impacts from defaults and rating migration. The impact of these adverse market movements was amplified by the partial lack of a tax offset as their severity led to inadmissibility of certain deferred tax assets. There was also an adverse impact from the announced settlement in the litigation case on monthly deduction rate adjustments on certain universal life insurance policies. These negative impacts more than offset the positive impact from normalized capital generation.
The estimated Solvency II ratio in the Netherlands increased to 249% on March 31, 2020, from 171% on December 31, 2019. This was mainly driven by the significant increase of the EIOPA volatility adjustment during the quarter. Other positive impacts from markets included the effect of lower interest rates due to an overhedged position on a Solvency II basis, and widening of credit spreads on the own employee pension scheme. Furthermore, equity markets had, on balance, a positive impact as the adverse effect of lower equities on own funds was more than offset by the symmetric adjustment in the Solvency II framework, lowering the required capital under the Standard Formula for illiquid investments due to declining markets. The main negative market impacts were from widening mortgage, corporate, and sovereign credit spreads, which lowered asset values. The negative impact of lowering the ultimate forward rate by 15 basis points was offset by the positive impact from a one-time tax item. Normalized capital generation had a positive impact and largely offset the EUR 100 million remittance to the Group in the first quarter.
The estimated Solvency II ratio in the United Kingdom increased to 160% on March 31, 2020, from 157% on December 31, 2019, and remained above the bottom-end of the target range of 145%. The increase was driven by normalized capital generation. Hedge programs to protect the Solvency II ratio against adverse market movements were effective. Market variance was a small positive overall on the Solvency II ratio as the negative impacts from lower interest rates and equity markets were more than offset by the positive impact of widening credit spreads on the own employee pension scheme.
The Core Tier-1 ratio of Aegon Bank declined slightly over the quarter to 19.7%. The negative impact from spread widening on the debt security portfolio and increases in expected credit loss on unsecured loans to consumers and small businesses was largely offset by aligning the risk-weighting of the basis adjustment to the overall mortgage portfolio. For more details on the capital position of Aegon Bank, we refer to Aegon Bank’s 2019 annual report.
|Holding excess cash|
|EUR millions||1Q 2020|
|Beginning of period|
|Capital injections / Acqusitions|
|Holding expenses and capital return|
|End of period|
|Mar. 31,||Dec. 31,|
|Aegon Group (EUR)|
|Eligible Own Funds|
|Consolidated Group SCR|
|Solvency II ratio 1|
|United States (USD)|
|The Netherlands (EUR)|
|Solvency II ratio|
|United Kingdom (GBP)|
|Solvency II ratio|
|Core Tier-1 ratio Aegon Bank|
|1 Please note that Aegon Bank is excluded from the Solvency II ratio of Aegon NL.|
|1Q 2020 income statement items: average rate 1 EUR = USD 1.1026 (4Q 2019: USD 1.1072).|
|1Q 2020 income statement items: average rate 1 EUR = GPB 0.8612 (4Q 2019: GBP 0.8599).|
|Balance sheet items: closing rate 1Q - 1 EUR = USD 1.0973 (USD 1.1225).|
|Balance sheet items: closing rate 1Q - 1 EUR = GBP 0.8849 (GBP 0.8473).|
Full version press release
Use this link for the full version of the press release
The conference call presentation is available on aegon.com as of 7.30 a.m. CET.
Conference call including Q&A
9:00 a.m. CET
Audio webcast on aegon.com
NL : +31 (0)20 703 8211
UK : +44 (0)330 336 9125
US : +1 720 543 0206
Two hours after the conference call, a replay will be available on aegon.com.
Publication dates 2020 results
First half year 2020 – August 13, 2020
Second half year 2020 – February 11, 2021
Aegon’s roots go back 175 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world’s leading financial services organizations, providing life insurance, pensions and asset management. Aegon’s purpose is to help people achieve a lifetime of financial security. More information on aegon.com/about.
|For segment reporting purposes underlying earnings before tax, net underlying earnings, commissions and expenses, operating expenses, income tax (including joint ventures (jv's) and associated companies), income before tax (including jv's and associated companies) and market consistent value of new business are calculated by consolidating on a proportionate basis the revenues and expenses of Aegon’s joint ventures and Aegon’s associates. Aegon believes that these non-IFRS measures provide meaningful information about the underlying results of Aegon's business, including insight into the financial measures that Aegon's senior management uses in managing the business. Among other things, Aegon's senior management is compensated based in part on Aegon's results against targets using the non-IFRS measures presented here. While other insurers in Aegon's peer group present substantially similar non-IFRS measures, the non-IFRS measures presented in this document may nevertheless differ from the non-IFRS measures presented by other insurers. There is no standardized meaning to these measures under IFRS or any other recognized set of accounting standards. Readers are cautioned to consider carefully the different ways in which Aegon and its peers present similar information before comparing them.|
Aegon believes the non-IFRS measures shown herein, when read together with Aegon's reported IFRS financial statements, provide meaningful supplemental information for the investing public to evaluate Aegon’s business after eliminating the impact of current IFRS accounting policies for financial instruments and insurance contracts, which embed a number of accounting policy alternatives that companies may select in presenting their results (i.e. companies can use different local GAAPs to measure the insurance contract liability) and that can make the comparability from period to period difficult.
|Aegon segment reporting is based on the businesses as presented in internal reports that are regularly reviewed by the Executive Board which is regarded as the chief operating decision maker.|
|The following table provides the reconciliation from the non-IFRS-EU measures underlying earnings before tax, income tax and income before tax to the most comparable IFRS-EU measure.|
|EUR millions||Segment total||Joint ventures and associates eliminations||Consolidated|
|Net Underlying earnings|
|Tax on underlying earnings|
|Underlying earnings before tax|
|Fair value items|
|Realized gains / (losses) on investments|
|Other income / (charges)|
|Income / (loss) before tax|
|Income tax from certain proportionately consolidated joint ventures and associates included in income before tax|
|Income tax (expense) / benefit|
|Of which income tax from certain proportionately consolidated joint ventures and associates included in income before tax|
|Net income / (loss)|
|New life sales is defined as new recurring premiums plus 1/10 of single premiums.|
|The present value, at point of sale, of all cashflows for new business written during the reporting period, calculated using approximate point of sale economics assumptions. Market consistent value of new business is calculated using a risk neutral approach, ignoring the investment returns expected to be earned in the future in excess of risk free rates (swap curves), with the exception of an allowance for liquidity premium. The Swap curve is extrapolated beyond the last liquid point to an ultimate forward rate. The market consistent value of new business is calculated on a post tax basis, after allowing for the time value financial options and guarantees, a market value margin for non-hedgeable non-financial risks and the costs of non-hedgeable stranded capital.|
|Return on equity is a ratio calculated by dividing the net underlying earnings after cost of leverage, by the average shareholders' equity excluding the revaluation reserve.|
|Reconciliation of operating expenses, used for segment reporting, to Aegon's IFRS based operating expenses.|
|First quarter 2020|
|Operating expenses for IFRS reporting|
|Operating expenses related to jv's and associates|
|Operating expenses in earnings release|
|New life sales, gross deposits and net deposits data include results from Aegon’s joint ventures and Aegon’s associates consolidated on a proportionate basis.|
|The calculation of the Solvency II capital surplus and ratio are based on Solvency II requirements. For insurance entities in Solvency II equivalent regimes (United States, Bermuda and Brazil) local regulatory solvency measurements are used. Specifically, required capital for the regulated entities in the US is calculated as one and a half times (150%) the upper end of the Company Action Level range (200% of Authorized Control Level) as applied by the National Association of Insurance Commissioners in the US, while the own funds is calculated by applying a haircut to available capital under the local regulatory solvency measurement of one time (100%) the upper end of the Company Action Level range. For entities in financial sectors other than the insurance sector, the solvency requirements of the appropriate regulatory framework are taken into account in the group ratio. The group ratio does not include Aegon Bank N.V. As the UK With-Profit funds is ring fenced, no surplus is taken into account regarding the UK With-Profit funds for Aegon UK and Group numbers.|
|The solvency II capital ratio reflects Aegon’s interpretation of Solvency II requirements and are not final until filed with the regulators. The solvency II capital calculation is subject to supervisory review on an ongoing basis.|
|The results in this release are unaudited.|
Cautionary note regarding non-IFRS-EU measures
This document includes the following non-IFRS-EU financial measures: underlying earnings before tax, income tax, income before tax, market consistent value of new business and return on equity. These non-IFRS-EU measures are calculated by consolidating on a proportionate basis Aegon’s joint ventures and associated companies. The reconciliation of these measures, except for market consistent value of new business and return on equity, to the most comparable IFRS-EU measure is provided in the notes to this press release. Market consistent value of new business is not based on IFRS-EU, which are used to report Aegon’s primary financial statements and should not be viewed as a substitute for IFRS-EU financial measures. Aegon may define and calculate market consistent value of new business differently than other companies. Return on equity is a ratio using a non-IFRS-EU measure and is calculated by dividing the net underlying earnings after cost of leverage by the average shareholders’ equity adjusted for the revaluation reserve. Aegon believes that these non-IFRS-EU measures, together with the IFRS-EU information, provide meaningful supplemental information about the underlying operating results of Aegon’s business including insight into the financial measures that senior management uses in managing the business.
Local currencies and constant currency exchange rates
This document contains certain information about Aegon’s results, financial condition and revenue generating investments presented in USD for the Americas and TLB, and in GBP for the United Kingdom, because those businesses operate and are managed primarily in those currencies. Certain comparative information presented on a constant currency basis eliminates the effects of changes in currency exchange rates. None of this information is a substitute for or superior to financial information about Aegon presented in EUR, which is the currency of Aegon’s primary financial statements.
The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:
- Changes in general economic and/or governmental conditions, particularly in the United States, the Netherlands and the United Kingdom;
- Changes in the performance of financial markets, including emerging markets, such as with regard to:
– The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios;
– The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and
– The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;
- Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties;
- Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition;
- Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries;
- The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;
- Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;
- Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;
- Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;
- Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets;
- Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war and pandemics, could result in material losses and significantly interrupt Aegon’s business;
- The frequency and severity of insured loss events;
- Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products;
- Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results;
- Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;
- Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations;
- Customer responsiveness to both new products and distribution channels;
- As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows;
- The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;
- Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess cash and leverage ratio management initiatives;
- Changes in the policies of central banks and/or governments;
- Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;
- Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products;
- Consequences of an actual or potential break-up of the European monetary union in whole or in part, or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;
- Changes in laws and regulations, particularly those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers;
- Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates;
- Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); and
- Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels.
This document contains information that qualifies, or may qualify, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (596/2014). Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
+31 (0) 70 344 8821